Last edition
News about "EyeBio"
Merck Initiates Phase 2b/3 Trial of MK-8748 for Neovascular Age-Related Macular Degeneration
Merck initiates a Phase 2b/3 trial of MK-8748 (Tiespectus), a bispecific antibody targeting Tie2 and VEGF pathways for treatment of neovascular age-related macular degeneration.
EyeBio | 04/04/2026 | By News Bureau
Merck Announces Acquisition of EyeBio
Merck has signed a definitive agreement under which Merck, through a subsidiary, will acquire EyeBio.
EyeBio | 30/05/2024 | By Aishwarya | 601
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy